People living with NCDs are at a higher risk of becoming severely ill if they contract COVID-19. NCDs are underlying health conditions that require you to take special care: cardiovascular diseases, diabetes, respiratory diseases, dementia, kidney disease and cancer.
NCDs and other chronic conditions make the immune system slow down, and it is more likely to get an infection like COVID-19. So we want to keep you healthy.
The South African Non-Communicable Disease Alliance (SANCDA) is proud to announce the first NCD’s Happy Hour Xchange on Thursday 18 March 2021 at 18:00 to discuss COVID-19 in South Africa, exploring the risk and priority of comorbidities as we enter the second year, preparing for the second phase of vaccinations, and preparing for the third wave.
The South African Non-Communicable Disease Alliance (SANCDA) is proud to announce the first NCD’s Happy Hour Xchange on Thursday 18 March 2021 at 18:00 to discuss COVID-19 in South Africa, exploring the risk and priority of comorbidities as we enter the second year, preparing for the second phase of vaccinations, and preparing for the third wave. (link: https://www.sancda.org.za/)
Dr Waasila Jassat, Public Health Medicine Specialist from the National Institute for Communicable Diseases (NICD) is our first Xpert
Waasila is responsible for the Daily Hospital Surveillance (DATCOV) report. To view the latest NICD report with comorbidities included.
Happy Hour Xchange is a series of knowledge Xpanding events informing and inspiring NCDs+ civil society organisations and activists to engage on diverse policy issues. Xperts Xchange key emerging facts and unknowns with us in an open and frank discussion via Zoom. Our aim is to Xpand the NCDs+ policy dialogue through engagement and co-production.
Tone: Mutually respectful, interactive, inquisitive and informal.
Frequency: Weekly or biweekly Thursdays for 1 hour between 18:00-19:00 SAST.
Format: A modern-day seminar. Xpert, NAG selected chair,
Part 1: Xpert – 15 minutes and Questions 15 minutes
Part 2: Xpert – 15 minutes and Questions 15 minutes
Questions can be submitted before and during a session.
Platform: virtual meeting via Zoom a NAG chair and Xpert guest
Suggested topics so far:
Targeted prevention Health Promotion Levy
Phase 2 vaccine rollout
Better Health Project SA report series on NCDs NSP related topics
Alignment of policy
Social & behavioural change communication
Monitoring and evaluate
Prioritisation and NCDs health care who says what
Costing models for NCDs care
The Cascades of care
Social and other determinants of health
Food security, nutrition and obesity.
Post-COVID-19 agenda – build back fairer.
Global diabetes Compact
Integrated people-centred health services.
Cobranding with other organisations will be possible.
Contact Dr Vicki Pinkney-Atkinson, Director of SANCDA on 083 383 8159 or email: [email protected] for more information.
Hydroxychloroquine does not reduce deaths from COVID-19 and may even cause unwanted damage, recent studies have found. According to the new Cochrane Review, the drug probably does not reduce the number of people needing mechanical ventilation.
“In addition, they note that no new trials of hydroxychloroquine or chloroquine for treating COVID-19 should be started,” the South African Medical Research Council (SAMRC) said on Tuesday. The findings are contained in the study published by authors based in India, South Africa, and the United Kingdom, who undertook the systematic review of studies that used chloroquine or hydroxychloroquine for treating or preventing COVID-19 disease.
It is also likely that hydroxychloroquine caused more unwanted effects than placebo in the trials undertaken. I think this underlines the importance of ensuring that we have reliable evidence even in an emergency situation like this pandemic where there is public pressure for rapid treatments and prevention options.
Dr Tamara Kredo, Cochrane South Africa, SAMRC
“They searched for studies that examined giving chloroquine or hydroxychloroquine to people with COVID-19; people at risk of being exposed to the virus; and people who had been exposed to the virus,” the SAMRC explained. According to the SAMRC, the public demand for a COVID-19 cure fuelled speculation that the drug might be effective based on unreliable research that did not meet the inclusion criteria of this review.
“The then US President Trump declared chloroquine a ‘game changer’ about a year ago, leading to global demand and confusion. The research community rapidly organised large trials, which demonstrated no evidence of an effect, and these trials are summarised in this review.”
The Council said the review authors included 14 relevant studies of which 12 were studies of chloroquine or hydroxychloroquine used to treat COVID-19 in 8 569 adults. Meanwhile, the two studies focused on whether hydroxychloroquine prevents COVID-19 in 3 346 adults who had been exposed to the virus but had no symptoms of infection. This included research from different countries, four in China and one each from Brazil, Egypt, Iran, Spain, Taiwan, the United Kingdom and North America and a global study in 30 countries.
According to the local author from Cochrane South Africa, Tamara Kredo, this review offers conclusive evidence that hydroxychloroquine has no impact on clinically important outcomes for both the prevention and treatment of COVID-19.
Senior author, Dr Tom Fletcher, said: “The review should put a line under using this drug to treat COVID-19. But some countries and health providers are still caught up in the earlier hype and prescribing the drug. We hope this review will help these practices end soon”. This Cochrane Review was co-ordinated by the Cochrane Infectious Diseases Group (CIDG), which has its editorial base at Liverpool School of Tropical Medicine (LSTM).
Cochrane South Africa (SA) is an internal research unit of the SAMRC and is part of the global, independent Cochrane network of researchers, professionals, patients, carers and people interested in health. Cochrane is a non-profit organisation that prepares and disseminates information on what works and what does not in healthcare. These reviews enable policymakers, health service providers and the public to make informed decisions about healthcare.
President of the European Commission, Ms Ursula von der Leyen, Director-General of the WHO, Dr Tedros Adhanom Ghebreyesus, CEO of Global Citizen, Mr Hugh Evans, Global Citizens and Friends,
South Africa is honoured once again to lend our support to Global Citizen, and to this Recover Better Together campaign. For the past 10 years, Global Citizen has been a leading voice for the involvement of governments, world leaders, philanthropists, activists, artists and the citizens of the world in ending extreme poverty.
When the coronavirus pandemic struck last year, Global Citizen responded swiftly, hosting the ‘One World: Together At Home’ benefit concert in support of healthcare workers on the frontline. The substantial pledges made for coronavirus relief at this event enabled NGOs around the world to help those most vulnerable.
The campaign we are launching today recognises that overcoming the COVID-19 pandemic is essential if we are to make any progress in tackling poverty. To achieve this, we must deepen cooperation to ensure equitable access to vaccines.
No person, no country and no region must be left behind. To fight the pandemic, we need to pool resources, capabilities, knowledge and intellectual property.
That is why we continue to call on world leaders to support the COVAX facility to ensure rapid and equitable access to COVID-19 vaccines for all countries. Applaud President Macron and EU that wealthier countries should donate 5% of their purchased vaccine stock to developing countries.
Another important step is to enable the transfer of medical technology for the duration of the pandemic. This will allow us to increase the production of COVID-19 vaccines and other medical products, lower prices and improve distribution to reach all corners of the world .
Alongside these efforts to overcome the pandemic, we must work together to end hunger, promote education and the resumption of learning, and protect the planet. By doing so, we will be contributing to a fair, just and inclusive recovery. The world will recover, it will recover better, and it will recover together. For the benefit of all leaving no one behind.
Government will in the next financial year avail an additional R8 billion to the health system for the country’s COVID-19 pandemic response.
This will be in addition to the R20 billion the state allocated in the 2020/21 financial year, Finance Minister Tito Mboweni said on Wednesday, while delivering the 2021 Budget Speech, in Parliament.
In a Budget Review document, the National Treasury said the funds were to enable the sector to expand prevention, screening, testing and hospital capacity.
The R8 billion, which will be allocated to provincial health departments through the provincial equitable share, is expected to enable the sector to sustain these activities and respond to possible future waves of COVID-19 infection.
“Provincial governments receive an additional R8 billion in 2021/22 to continue the public health response to the pandemic, and the potential for additional waves of infection. Provinces can mitigate the negative impact of COVID-19 and the associated lockdowns on their revenues by improving efficiency, particularly in the procurement of health equipment,” said the Minister.
In total, the health expenditure function will over the medium term make up 14.2 percent of total government spending, declining from R247 billion in 2020/21 to R245 billion in 2023/24.
“Provincial health departments receive about 92 percent (R678.7 billion) of these medium-term allocations.
Reductions to the sector, mostly focused on compensation spending, are estimated at about R50.3 billion over the 2021 MTEF period,” the document reads.
To achieve this, other reductions would be required from health departments to increase efficiency. This included generating savings through centralised procurement of certain goods, reducing variations in unit costs in HIV programmes and improving management of overtime costs.
The COVID-19 pandemic has had a massive impact on the South African health system. As at 16 February 2021, the country had 1.5 million confirmed cases and over 137 000 excess deaths as reported by the South African Medical Research Council.
Over the MTEF period, R29.4 million is allocated to Tygerberg Regional Hospital and R100 million to Klipfontein Regional Hospital in the Western Cape through the health facility revitalisation grant.
Better late than never. And it is only until October last year. Comorbidities are published once and not routinely by NICD. Oh now, the second wave is over “we will publish another list.” Really?
This requires some myth-busting action from the National Department of Health. I am tired of the comorbidities listed in media interviews by NDoH officials as going in this order: HIV, TB and more recently malaria (really). Then perhaps diabetes…. take a look and weep. Shame